Grant opportunity
FORCE Joint Transnational Call 2027
A transnational funding call for pragmatic clinical trials that address rare cancers and cancers with limited treatment options while integrating patient-relevant quality-of-life outcomes.
- Funder
- FORCE4Cancer Partnership
- Pre-proposals close 21 September 2026 at 14:00 CET
- Pre-proposals close 21 September 2026 at 14:00 CET: Sep 21, 2026
- Award
- Approximately EUR 13 million in participating-funder commitments
- Applicant
- Eligible multinational research consortia proposing pragmatic clinical trials in rare cancers or cancers with limited treatment options under the participating funders' national rules.
- Discipline
- Cancer and Clinical Research
- Region
- Europe and participating partner countries
- Posted
- Aug 18, 2026
Call summary
Overview
The FORCE partnership is supporting practice-oriented multinational cancer trials designed to improve treatment evidence and outcomes in areas where commercial incentives or patient numbers are limited.
Who can apply
Applicants must form an eligible transnational consortium and comply with both the joint call text and the national or regional rules of every participating funding organisation.
What it supports
- Pragmatic clinical trials
- Rare cancers
- Cancers with limited therapeutic options
- Patient-centred quality-of-life outcomes
Funding and duration
- Approximately EUR 13 million is committed across participating funders
- Individual awards and eligible costs follow the applicable national or regional annexes
Pre-proposals close 21 September 2026 at 14:00 CET
Pre-proposals close 21 September 2026 at 14:00 CET: Sep 21, 2026
How to apply
Review the joint call text and funder annexes, form the required consortium, and submit the pre-proposal through the official FORCE call route.
Call details
Source-based overview
Proposals should address a clear clinical need, use a feasible multinational design and embed outcomes that matter to patients. The joint call and each participating funder's rules together form the controlling application guidance.
Eligibility
Applicants must form an eligible transnational consortium and comply with both the joint call text and the national or regional rules of every participating funding organisation.
Funding and benefits
Approximately EUR 13 million is committed across participating funders
Individual awards and eligible costs follow the applicable national or regional annexes
Themes and supported activities
Pragmatic clinical trials
Rare cancers
Cancers with limited therapeutic options
Patient-centred quality-of-life outcomes
Deadline and timeline
Pre-proposals close 21 September 2026 at 14:00 CET: Pre-proposals close 21 September 2026 at 14:00 CET: Sep 21, 2026.
Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.
How to apply
Review the joint call text and funder annexes, form the required consortium, and submit the pre-proposal through the official FORCE call route.
Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.